About this Research Topic
Pharmacogenomics is central to the advancement of personalized medicine, promising improved treatment efficacy and reduced adverse effects through the integration of genetic insights into clinical practice. Despite the availability of genotyping technologies and their decreasing costs, significant challenges remain in mainstreaming pharmacogenomics. These include the need to adapt clinical pathways, educate healthcare professionals, account for ethnic diversity and integrate genomic data into clinical decision-making processes.
Current research has identified numerous gene-drug interactions that influence drug efficacy and toxicity. For instance, variants in genes encoding drug-metabolizing enzymes (e.g., CYP2C19, CYP2D6) and drug targets have been associated with variable drug responses. Despite these discoveries, the translation of pharmacogenomic findings into clinical practice has been slow and inconsistent across healthcare systems.
The aim of this Research Topic is to offer a comprehensive exploration of pharmacogenomics, emphasizing real-world applications, studies on diverse populations, and the integration of novel biomarkers in clinical settings. By highlighting cutting-edge research and practical implementations with data from real-world evidence, this collection aims to show the transformative potential of pharmacogenomics in personalized medicine.
The Research Topic will welcome manuscripts which explore the following thematics:
• Real-World Application of Pharmacogenetics: This section seeks articles that explore concrete examples and case studies where pharmacogenetic insights have been applied in clinical settings. We aim to gather evidence on the practical benefits and challenges of implementing pharmacogenomics in everyday healthcare.
• Pharmacogenetics in Diverse Populations: This section invites articles that focus on pharmacogenetic research in various populations, beyond the standard Caucasian demographic. The goal is to highlight inclusive research practices and address the need for genetic diversity in ensuring the benefits of pharmacogenomics are accessible to all patient groups.
• Integrating new Biomarkers and prediction models in the clinic: We seek contributions that cover the latest advancements in the clinical application of pharmacogenetic knowledge. Both in regards to new genetic biomarkers as well as new (computational) approaches to interpret pharmacogenetics results. Articles should discuss the processes and challenges of integrating novel biomarkers or tools in patient care.
By addressing these critical areas, this Research Topic aims to provide valuable insights into the current and future landscape of pharmacogenomics with an emphasis on current challenges in implementations.
Please note: If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for selecting the specific data studied should be provided. Studies related to natural compounds, herbal extracts, or traditional medicine products, are outside the scope of this Research Topic and should instead be submitted to the specialty section Ethnopharmacology. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or experimental validation, will not be included in this Research Topic.
Current research has identified numerous gene-drug interactions that influence drug efficacy and toxicity. For instance, variants in genes encoding drug-metabolizing enzymes (e.g., CYP2C19, CYP2D6) and drug targets have been associated with variable drug responses. Despite these discoveries, the translation of pharmacogenomic findings into clinical practice has been slow and inconsistent across healthcare systems.
The aim of this Research Topic is to offer a comprehensive exploration of pharmacogenomics, emphasizing real-world applications, studies on diverse populations, and the integration of novel biomarkers in clinical settings. By highlighting cutting-edge research and practical implementations with data from real-world evidence, this collection aims to show the transformative potential of pharmacogenomics in personalized medicine.
The Research Topic will welcome manuscripts which explore the following thematics:
• Real-World Application of Pharmacogenetics: This section seeks articles that explore concrete examples and case studies where pharmacogenetic insights have been applied in clinical settings. We aim to gather evidence on the practical benefits and challenges of implementing pharmacogenomics in everyday healthcare.
• Pharmacogenetics in Diverse Populations: This section invites articles that focus on pharmacogenetic research in various populations, beyond the standard Caucasian demographic. The goal is to highlight inclusive research practices and address the need for genetic diversity in ensuring the benefits of pharmacogenomics are accessible to all patient groups.
• Integrating new Biomarkers and prediction models in the clinic: We seek contributions that cover the latest advancements in the clinical application of pharmacogenetic knowledge. Both in regards to new genetic biomarkers as well as new (computational) approaches to interpret pharmacogenetics results. Articles should discuss the processes and challenges of integrating novel biomarkers or tools in patient care.
By addressing these critical areas, this Research Topic aims to provide valuable insights into the current and future landscape of pharmacogenomics with an emphasis on current challenges in implementations.
Please note: If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for selecting the specific data studied should be provided. Studies related to natural compounds, herbal extracts, or traditional medicine products, are outside the scope of this Research Topic and should instead be submitted to the specialty section Ethnopharmacology. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or experimental validation, will not be included in this Research Topic.
Keywords: Pharmacogenomics, Pharmacogenetics, Personalized Medicine, Genetic Diversity, Clinical Implementation, Biomarkers, exploratory Studies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
